New malaria pill for tiny infants studied, but trial stopped early
NCT ID NCT04300309
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new, easy-to-dissolve malaria tablet in infants and newborns weighing less than 5 kg who had uncomplicated malaria. The goal was to see how the medicine worked in the body, how safe it was, and how well it treated the infection. The trial was stopped early after enrolling 28 participants.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PLASMODIUM FALCIPARUM MALARIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Novartis Investigative Site
Nanoro, Burkina Faso
-
Novartis Investigative Site
Ouagadougou, Burkina Faso
-
Novartis Investigative Site
Kisantu, Bas Kongo, Democratic Republic of the Congo
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new malaria vaccine slash childhood cases? a massive real-world test seeks answers.
- Malaria prevention study pulled before it began
- Could targeted drug dosing stamp out malaria in thai hotspots?
- New vaccines aim to block malaria transmission in africa
- Mass Drug-Vaccine combo takes on malaria in 10,000-Person trial
- Half-Dose malaria vaccine could double protection for millions